Income statement
USD
Annual
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | 32M | 20M |
| Gross Profit | 32M | 20M |
| Operating Income | -235M | -197M |
| EBITDA | -208M | -164M |
| Net Income | -203M | -174M |
| EPS (Diluted) | — | — |
Financial Services
Live Price
Offline$16.53
+0.67% today
Window Change
+9.64%
Window
Feb 27, 2026 → Jun 17, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 77 bars · Feb 27, 2026 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Generate Biomedicines, Inc. (GENB) is a Financial Services stock with a market cap of $1.62B and listed on NASDAQ. The stock last traded around $16.53 and up 9.6% across the available one-year price window (Feb 27, 2026 → Jun 17, 2026). Baseline metrics include revenue growth of +55.9%, EPS growth of -196.4%, a dividend yield of 0.0%. What stands out right now is revenue +55.9%, EPS -196.4%, free cash flow -68.4% with operating margin -737.0% and ROIC -89.4%. Valuation already assumes a fairly strong business story at price/sales 50.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GENB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GENB
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GENB Max Drawdown
-26.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for GENB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$20.5M
-35.9% YoY
FY Net Income
-$173.8M
+14.5% YoY
Free Cash Flow
-$121.2M
+40.6% YoY
Revenue Growth
+55.9%
EPS Growth
-196.4%
Gross Margin
100.0%
Net Margin
-637.0%
Income statement
USD
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | 32M | 20M |
| Gross Profit | 32M | 20M |
| Operating Income | -235M | -197M |
| EBITDA | -208M | -164M |
| Net Income | -203M | -174M |
| EPS (Diluted) | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 |
|---|---|---|
| Cash & Equivalents | 122M | 176M |
| Total Assets | 330M | 518M |
| Total Liabilities | 953M | 953M |
| Shareholder Equity | -616M | -435M |
| Total Debt | 69M | 77M |
| Net Debt | -53M | -99M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
118M
+41.3% YoY
Capital Expenditures
3M
+1.9% YoY
Free Cash Flow
121M
+40.6% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-737.0%
Net Margin
-637.0%
ROE
38.7%
Debt / Equity
-0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.